ClinicalTrials.gg
RecruitingNCT04637620Updated Oct 23, 2026

NMDA Modulation in Major Depressive Disorder

A Phase 2 interventional study of NMDAE and Sertraline in Major Depressive Disorder, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by China Medical University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Jun 2017, registered Oct 2020).
  • Started Jun 2017; still recruiting 9 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 69 studies in Depressive Disorder, Major with a site in Taiwan — 13 open to participants now, 13 under way, 6 of them phase 3. Depressive Disorder, Major · Taiwan.

Planned enrollment
39th of 64
90 · median 128
Started
2017
with 3 others
Phase 2
8 of 69
2 open now
Primary completion
2026-11
later than 2 of 12 live
Registered
45th of 69
by date
Lead sponsor
7 of 69
China Medical University Hospital

Among the 69 studies in Depressive Disorder, Major with a site in Taiwan, this one is the 39th largest by planned enrollment of the 64 interventional ones that give a count, is one of 4 that started in 2017, is one of 8 in phase 2, reaches primary completion later than 2 of the 12 other live ones, and was the 45th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

13 of the 69 studies in Depressive Disorder, Major with a site in Taiwan are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Depressive Disorder, Major with a site in Taiwan, or all of them as a file.
02

Study summary

Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of an NMDA enhancer (NMDAE) in the treatment of MDD in the adults.

Read the detailed description

Major depressive disorder (MDD) is a complex and multi-factorial disorder. Most of the current antidepressants are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. Many patients have significant side effects after treatment with antidepressants which hamper the motivation for treatment and medication adherence. NMDA hypofunction has been implicated in the pathophysiology of depression. MDD is often associated with cognitive deficits which are not necessarily recovered by current antidepressants. The NMDA receptor regulates synaptic plasticity, memory, and cognition. In our previous studies, cognitive improvement has been observed with treatment of NMDA enhancers. Therefore, this study will examine the efficacy and safety as well as cognitive function improvement of NMDAE in the treatment of MDD in the general adults by comparing with sertraline (a selective serotonin reuptake inhibitor [SSRI]) and placebo. The investigators will enroll non-elderly adult patients with MDD for an 8-week treatment. All patients will be randomly assigned into three groups: NMDAE, sertraline, or placebo. The investigators will biweekly measure clinical performances and side effects. Cognitive functions will be assessed at baseline and at endpoint of treatment by a battery of tests. The efficacy of three groups will be compared.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major depressive disorder
  • NMDA
  • Selective serotonin reuptake inhibitor
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (American Psychiatric Association) diagnosis of MDD
  • 17-item Hamilton Rating Scale for Depression total score ≥ 18
  • Free of antidepressant drugs for at least 2 weeks
  • Agree to participate in the study and provide

Exclusion criteria

Exclusion Criteria:

  • Current substance abuse or history of substance dependence in the past 6 months
  • History of epilepsy, head trauma, stroke or other serious medical or neurological illness which may interfere with the study
  • Bipolar depression, schizophrenia or other psychotic disorder
  • Moderate-severe suicidal risks
  • Severe cognitive impairment
  • Initiating or stopping formal psychotherapy within six weeks prior to enrollment
  • A history of severe adverse reaction to SSRIs
  • A treatment-resistant history (that is, they have failed to respond to two or more different classes of antidepressants with adequate dosage and treatment duration
  • A history of previously received electroconvulsive therapy
  • Inability to follow protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    NMDAE

    An NMDA enhancer

    Drug: NMDAE

  • Active comparator
    SSRI

    Sertraline (selective serotonin reuptake inhibitor)

    Drug: Sertraline

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo Cap

Interventions

  • DrugNMDAE

    Use of an NMDA enhancer for the treatment of MDD

  • Use of SSRI as an active comparator

  • DrugPlacebo Cap

    Use of placebo as a comparator

06

What researchers measure

Primary outcomes

  1. Change in Hamilton Rating Scale for Depression

    Assessment of depressive symptoms Minimum value: 0, maximum value:52, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 8

  2. Change in Global Assessment of Functioning

    Assessment of global improvement. Minimum value: 1, maximum value:100, the higher scores mean a better outcome.

    Time frame: Week 0, 2, 4, 6, 8

Secondary outcomes

  1. Change in Perceived Stress Scale

    Assessment of stress and anxiety symptoms Minimum value: 0, maximum value:56, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 8

  2. Visual Analogue Scale (VAS)

    Assessment of pain Minimum value: 0, maximum value:10, the higher scores mean a worse outcome.

    Time frame: week 0, 2, 4, 6, 8

  3. Clinical Global Impression

    Time frame: week 0, 2, 4, 6, 8

  4. Quality of life (SF-36)

    Time frame: week 0, 8

  5. Visual Continuous Performance Test

    Assessment of sustained attention

    Time frame: week 0, 8

  6. Wisconsin Card Sorting Test

    Assessment of abstract and shift set

    Time frame: week 0, 8

  7. Logical Memory Test of the Wechsler Memory Scale

    Assessment of episodic memory

    Time frame: week 0, 8

  8. Digit Span

    Assessment of verbal working memory

    Time frame: week 0, 8

  9. Spatial Span

    Assessment of nonverbal working memory

    Time frame: week 0, 8

  10. Category Fluency

    Assessment of speed of processing

    Time frame: week 0, 8

  11. Trail Marking A

    Assessment of speed of processing

    Time frame: week 0, 8

  12. WAIS-III Digit Symbol-Coding

    Assessment of speed of processing

    Time frame: week 0, 8

  13. Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) V2.0

    Assessment of social cognition

    Time frame: week 0, 8

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2017 (actual). Primary completion is estimated for Nov 2026, 113 months after the start.

Of 99 non-industry phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 57. This study's planned 113 months is above that.

Counting every sponsor, half of 198 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2020
First posted
Nov 20, 2020
StartActual
Jun 1, 2017
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and index terms
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04637620
Collaborators
Ministry of Science and Technology, Taiwan
Responsible party
Sponsor
First posted
Nov 20, 2020
Start date
Jun 1, 2017
Primary completion
Nov 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 23, 2026

Study contacts

Hsien-Yuan Lane, M.D., Ph.D
Contact
hylane@gmail.com
886 4 22052121 ext. 1855

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion